Search clinical trials for: Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)

Total 2284 results

Nantes University Hospital

Completed

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)

Virus-HIV

France
Huahui Health

Active, not recruiting

A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

Chronic HBV Infection

China
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Hepatitis B | Hepatitis B, Chronic | HBV

Canada, United Kingdom
University of California, Davis

Completed

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

HIV Infections

United States
Boehringer Ingelheim

Completed

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

HIV Infections
Kirby Institute
Merck Sharp & Dohme LLC; amfAR, The Foundation for AIDS Research; Abbott

Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)

HIV Infections

Taiwan, Australia, Argentina, Singapore, India, France, South Africa, Chile, Germany, Hong Kong, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, United Kingdom
Boehringer Ingelheim

Completed

Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

HIV Infections
French National Agency for Research on AIDS and...

Terminated

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

HIV Infections | HIV-Associated Lipodystrophy Syndrome

France
Shire

Completed

Maribavir for Prevention of CMV After Stem Cell Transplants

Cytomegalovirus Infection

United States
French National Agency for Research on AIDS and...

Terminated

Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

HIV Infections | HIV Lipodystrophy Syndrome

France
Shire

Terminated

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

Healthy Volunteers

United States
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States
Boehringer Ingelheim

Terminated

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

HIV Infections

United States, Argentina, Brazil, Canada, Germany, Italy, Spain
Pharmasset

Completed

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

HIV Infections

United States, Argentina, Mexico, Panama
University of Minnesota
Merck Sharp & Dohme LLC

Withdrawn

Raltegravir Activity In Lymphoid Tissues

HIV Infections | HIV Infection

United States
Assembly Biosciences

Terminated

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Chronic Hepatitis B

United States, Canada, Hong Kong, New Zealand, United Kingdom
Kirby Institute
National Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare and other collaborators

Withdrawn

Inflammation and Co-Infections in D²EFT (i2-D²EFT)

Cytomegalovirus Infections | Human Papilloma Virus | HIV-infection/Aids | Human Herpesvirus 4 Infections | Human Herpesvirus 8 Infection
Kirby Institute
National Health and Medical Research Council, Australia; National Institute... and other collaborators

Active, not recruiting

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

HIV Infections

Mexico, Thailand, Malaysia, Argentina, Brazil, India, Nigeria, South Africa, Chile, Colombia, Guinea, Indonesia, Mali, Zimbabwe
Janssen-Cilag S.p.A.

Completed

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients (MONARCH)

Human Immunodeficiency Virus 1
Fudan University

Unknown

Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP (IHBVRL)

Lymphoma

China
Bristol-Myers Squibb

Completed

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

HIV-Associated Lipodystrophy Syndrome

Spain, Italy, United States, Canada, France, Mexico, United Kingdom, Poland, Germany
Northwell Health
Cohen Children's Medical Center

Available

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Neuroblastoma | Pheochromocytoma

United States
GlaxoSmithKline

Completed

Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults

HIV Infections
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients

HIV Infections

United Kingdom
Henlix, Inc

Unknown

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

Hepatitis B, Chronic

Taiwan
IRCCS San Raffaele
Hoffmann-La Roche; Abbott

Unknown

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

HIV Infections | Hepatitis C

Italy
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

HIV Infection

Puerto Rico, United States, Argentina, Brazil, South Africa, Uganda, Zambia, Haiti, Kenya, Malawi, Tanzania, Thailand, Zimbabwe
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Bristol-Myers Squibb

Completed

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Completed

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

HIV Infections

United States, Puerto Rico
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Assembly Biosciences

Terminated

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Chronic Hepatitis B

Hong Kong, United States, New Zealand
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

HIV-1 Infection
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
Enyo Pharma
Parexel; Novotech (Australia) Pty Limited; Synteract, Inc.; Eurofins

Terminated

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Hepatitis B, Chronic

Australia, Hong Kong, Korea, Republic of, Poland
Sun Yat-sen University
First People's Hospital of Foshan; Eighth Affiliated Hospital, Sun Yat-sen...

Recruiting

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (IFNA2/ISGs)

Hepatitis B

China
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, China, Germany, South Africa, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Thailand, Mexico, Uganda
Pedro Cahn
Abbott

Completed

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. (GARDEL)

HIV Infection

Argentina
Bristol-Myers Squibb

Completed

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

HIV

Germany, United Kingdom
Kirby Institute

Completed

MARCH Renal Substudy (MARCHrenal)

Proteinuria | HIV

Canada, Australia, Germany, Argentina, Japan, Thailand, United Kingdom, Mexico
University of California, San Francisco
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (PROMOTE-PEDS)

HIV Infections | Malaria

Uganda
Kirby Institute

Active, not recruiting

Body Composition Sub-study of the D2EFT Trial

HIV Infections

Malaysia, Zimbabwe, India, South Africa, Thailand
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
Catholic University of the Sacred Heart

Completed

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

HIV Infections | HIV/AIDS | Antiretroviral Therapy

Italy
Universidad Peruana Cayetano Heredia
Merck Sharp & Dohme LLC

Completed

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

HTLV-I Infections | Tropical Spastic Paraparesis

Peru
Association Pour la Recherche en Infectiologie

Unknown

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients (NNNB)

HIV

France
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
Tibotec Pharmaceuticals, Ireland
Raltegravir is provided by Merck.

Completed

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

HIV Infections
Hospitales Universitarios Virgen del Rocío

Completed

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (RAET)

HIV Infections | HIV-1 Infection

Spain

3

Subscribe